Prenatal Stress and the Developing Brain: Postnatal Environments Promoting Resilience
A placebo-controlled phase 2 RCT testing pimavanserin in 117 PD patients with moderately severe ICDs has been completed but results have not yet been made public (PIMPARK study, NCT03947216)
(2007) 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Conversely, some individuals who initially tolerated high doses find that after substantial weight loss, lower doses provide adequate maintenance with fewer side effects
Doctronic.ai can help you assess your symptoms and determine the best course of action based on your specific situation